YposKesi

16 articles about YposKesi

• Yposkesi’s clinical batches of G1XCGD lentiviral vector used in rare immune system disease study

  1/29/2020

  International research team published initial clinical trial results in Nature Medicine of nine X-Linked Chronic Granulomatous Disease (CGD) patients

• Yposkesi selected to produce clinical and large-scale commercial material of micro-dystrophin for Genethon and Sarepta Therapeutics program

  1/9/2020

  Its capacity to produce AAV (Adeno Associated Virus) materials at large-scale will support Genethon and Sarepta’s project to take micro-dystrophin to clinical trials this year

• Yposkesi to host roundtable on challenges in gene therapy manufacturing at the Cell and Gene Meeting on the Mesa, October 2-4

  9/24/2019

  As more gene therapies advance to clinical trials, participants will discuss which are the best strategies for manufacturing to scale

• Yposkesi’s viral vectors used in gene therapy-based clinical trial

  9/9/2019

  EuroFanColen researchers published in Nature Medicine first clinical results for Fanconi anemia patients

• Axovant and Yposkesi sign strategic gene therapy development and manufacturing partnership

  6/20/2019

  Partnership secures access to reserved cGMP capacity and resources at Yposkesi for manufacturing to support the global development and commercialization of Axovant’s gene therapy programs

• Servier appoints Yposkesi for lentiviral vector GMP-manufacturing in CAR-T cell development technology

  6/5/2019

  Service agreement gives Servier access to Yposkesi’s robust production capacity

• Yposkesi chairman Dr. Frederic Revah to speak on ‘Manufacturing and the CDMO Perspective’

  4/23/2019

  Dr. Revah will join fellow industry panelists at the Cell and Gene Meeting on the Med in Barcelona to discuss strategies for gene therapy manufacturing, on April 23rd

• CDMO Yposkesi appoints new Director of Viral Vector Manufacturing Operations

  4/23/2019

  With 15 years’ bioproduction and cell & gene therapy expertise, Morad El Gueddari will take charge of Yposkesi’s industrial-scale viral vector manufacturing

• Yposkesi enters into agreement in principle for strategic partnership with Axovant to expand Axovant’s gene therapy manufacturing capacity

  11/28/2018

  In the framework of a preferred partnership, Yposkesi plans to grant Axovant access to dedicated cGMP capacity and manufacturing resources to further support the global development and commercialization of Axovant’s AAV-based gene therapy programs

• Yposkesi appoints Dr. Fraser Wright as senior advisor

  7/13/2018

  With extensive experience in gene therapy vector manufacturing, Dr. Wright, scientific co-founder and former CTO of Spark Therapeutics, will support Yposkesi’s innovation in viral vector design, production and characterization

• Yposkesi Presented its Latest Progress in Viral Vectors Production at the Cell & Gene Therapy World Conference in Miami

  1/26/2018

  The international Cell & Gene Therapy World conference gather nearly 1,300 industry professionals from more than 30 countries.

• YposKesi To Attend "Bpifrance Inno Génération" On October 12th, 2017 In Paris

  10/6/2017

• YposKesi To Attend Cell & Gene Therapy Europe Event September 20 - 21, 2017 In Berlin

  9/13/2017

• YposKesi To Attend 2017 BIO International Convention June 19 - 22, 2017 In San Diego

  6/13/2017

• YposKesi Announces The Appointment Of 3 New Members To Its Executive Committee

  5/31/2017

• YposKesi Welcomes Alain Lamproye, An Expert In Industrial Bioproduction, As Its Chief Executive Officer

  2/28/2017